CoChat

Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma

Open access

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Background: Transforming growth factor-β (TGF-β) pathway is involved in primary tumor progression and in promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore, blockage of TGF-β pathway signaling via an inhibitor could be a valuable tool in CRC treatment. Methods: To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by methyl thiazolyl tetrazolium (MTT) and bromo-2′-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers were stained, respectively. Results: Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70, P > 0.05) in treated SW-48 cells with SD-208 compared to controls. Conclusion: Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human colorectal cancer model at least using SW-48 cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2008-2231-22-47

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Continuous culture of SW-48 cells and treatment with SD-208. The cells were grown as monolayer epithelial-like morphology. SW-48 cells after treatment by DMSO alone as control (A), SD-208 concentrations 0.5 μM (B), 1 μM (C) and 2 μM (D).
Figure 1 Continuous culture of SW-48 cells and treatment with SD-208. The cells were grown as monolayer epithelial-like morphology. SW-48 cells after treatment by DMSO alone as control (A), SD-208 concentrations 0.5 μM (B), 1 μM (C) and 2 μM (D).CC BY · PubMed Central
Figure 2 Effect of SD-208 on the cell growth and proliferation of the SW-48 cells. SW-48 cells were treated by 0.5, 1 and 2 μM for 48 h. Cell proliferation was examined by MTT and BrdU assays as described in methods. A: MTT assay of SW-48 cells after treatment with SD-208 in comparison with controls (untreated and treated with DMSO). B: BrdU assay of SW-48 cells after treatment with SD-208 comparison with controls (untreated and treated with DMSO). All data are reported as the percentage change in comparison with the controls, which were arbitrarily assigned 100% cell proliferation. Analysis of one-way ANOVA was used to compare the cell proliferation of SW-48 cells in different concentrations of SD-208 to control. P value < 0.05 was regarded as statistically significant. Results are expressed as the mean ± SEM from three independent experiments.
Figure 2 Effect of SD-208 on the cell growth and proliferation of the SW-48 cells. SW-48 cells were treated by 0.5, 1 and 2 μM for 48 h. Cell proliferation was examined by MTT and BrdU assays as described in methods. A: MTT assay of SW-48 cells after treatment with SD-208 in comparison with controls (untreated and treated with DMSO). B: BrdU assay of SW-48 cells after treatment with SD-208 comparison with controls (untreated and treated with DMSO). All data are reported as the percentage change in comparison with the controls, which were arbitrarily assigned 100% cell proliferation. Analysis of one-way ANOVA was used to compare the cell proliferation of SW-48 cells in different concentrations of SD-208 to control. P value < 0.05 was regarded as statistically significant. Results are expressed as the mean ± SEM from three independent experiments.CC BY · PubMed Central
Figure 3 A representative of colorectal adenocarcinoma model. Tumor implantation; athymic nude mice implanted by SW-48 cell line, the cells were grown as tumor xenografts after 10 days. Cancer-bearing nude mice were treated with 50 mg/kg/day of SD-208 (A) or without SD-208 (B).
Figure 3 A representative of colorectal adenocarcinoma model. Tumor implantation; athymic nude mice implanted by SW-48 cell line, the cells were grown as tumor xenografts after 10 days. Cancer-bearing nude mice were treated with 50 mg/kg/day of SD-208 (A) or without SD-208 (B).CC BY · PubMed Central
Figure 4 A representative results of pathological examinations of nude mice tumors with or without SD-208 treatment. A: tumors of nude mice treated with 50 mg/kg/day stained with H&E. B: H&E staining of tumor tissues of control. No significant difference histologically was observed (P > 0.05).
Figure 4 A representative results of pathological examinations of nude mice tumors with or without SD-208 treatment. A: tumors of nude mice treated with 50 mg/kg/day stained with H&E. B: H&E staining of tumor tissues of control. No significant difference histologically was observed (P > 0.05).CC BY · PubMed Central
Figure 5 Colon adenocarcinoma (grade IV) stained immunohistochemically with anti-Ki-67. Positive immunoreactive showing brown nuclear expression of Ki-67 with a large number (~80%) of stained nuclei reflecting active cellular proliferation in the treated nude mice with SD-208 (A) and control (B): Immunohischemical assay showed no significant difference between tests and controls in terms of cellular proliferation (P > 0.05).
Figure 5 Colon adenocarcinoma (grade IV) stained immunohistochemically with anti-Ki-67. Positive immunoreactive showing brown nuclear expression of Ki-67 with a large number (~80%) of stained nuclei reflecting active cellular proliferation in the treated nude mice with SD-208 (A) and control (B): Immunohischemical assay showed no significant difference between tests and controls in terms of cellular proliferation (P > 0.05).CC BY · PubMed Central
Figure 6 Colon adenocarcinoma (grade IV) stained immunohistochemically with anti-CD34. The paraffin embedded sections of tumor tissues were stained with anti-CD34 antibody and positive immunoreactive indicating brown cytoplasmic membrane of endothelial cells and marked microvessel's proliferation. Microvessel density (MVD) was ~40 microvessel/mm2. SD-208-treated tumors (A) vs controls (B) revealed no significant immunohistologically differences (P > 0.05). Note the prominent vascularity. Arrows indicate CD34 staining of the cytoplasmic membrane.
Figure 6 Colon adenocarcinoma (grade IV) stained immunohistochemically with anti-CD34. The paraffin embedded sections of tumor tissues were stained with anti-CD34 antibody and positive immunoreactive indicating brown cytoplasmic membrane of endothelial cells and marked microvessel's proliferation. Microvessel density (MVD) was ~40 microvessel/mm2. SD-208-treated tumors (A) vs controls (B) revealed no significant immunohistologically differences (P > 0.05). Note the prominent vascularity. Arrows indicate CD34 staining of the cytoplasmic membrane.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 33

Metadata

Authors
Akbari, A., Amanpour, S., Muhammadnejad, S., Ghahremani, M. H., Ghaffari, S. H., Dehpour, A. R., Mobini, G. R., Shidfar, F., Abastabar, M., Khoshzaban, A., Faghihloo, E., Karimi, A., & Heidari, M.
Affiliations
  • Tehran University of Medical Sciences (IR)
  • Shariati Hospital (IR)
  • Mazandaran University of Medical Sciences (IR)
  • Farabi Hospital (IR)
  • Iran University of Medical Sciences (IR)
Corresponding author
Heidari, Mansour
Venue
DARU Journal of Pharmaceutical Sciences
Published
2014-06-05
Volume
22
Issue
1
Pages
47-47
ISSN
  • 1560-8115 (ISSN-L)
  • 2008-2231
OpenAlex
W2163340072
Cited by
33
References
26
Citations by year
2026: 1 · 2024: 2 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 6 · 2016: 3 · 2015: 2 · 2014: 1
FWCI
1.64
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • DARU Journal of Pharmaceutical Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Tehran University of Medical Sciences and Health Services
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
SD-208, TGF-beta signaling, colon adenocarcinoma, colorectal cancer, tumor cell proliferation, angiogenesis, anticancer activity
MeSH terms
Adenocarcinoma, Animals, Antineoplastic Agents, Colonic Neoplasms, Female, Humans, Mice, Inbred C57BL, Neovascularization, Pathologic, Pteridines, Transforming Growth Factor beta, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma. https://app.cochat.ai/papers/10.1186/2008-2231-22-47
The paper
Akbari, A., Amanpour, S., Muhammadnejad, S., Ghahremani, M. H., Ghaffari, S. H., Dehpour, A. R., Mobini, G. R., Shidfar, F., Abastabar, M., Khoshzaban, A., Faghihloo, E., Karimi, A., & Heidari, M. (2014). Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma. DARU Journal of Pharmaceutical Sciences. https://doi.org/10.1186/2008-2231-22-47

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.